Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

James C. Yao; Jonathan Strosberg; Nicola Fazio; Marianne Pavel; Philippe Ruszniewski; Emily K. Bergsland; D. Li; Salvatore Tafuto; Nitya Raj; Davide Campana; Susumu Hijioka; Markus Raderer; Rosine Guimbaud; Pablo Gajate; Sara Pusceddu; Albert Reising; Evgeny Degtyarev; Bijoyesh Mookerjee; Paola Aimone; Simron Singh

doi:10.1093/annonc/mdy293.001

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Background: PDR001 is a high-affinity, humanized, anti-PD-1 IgG4 antibody that blocks PD-L1 & PD-L2 binding to PD-1. A phase 2, multi-center study assessed the efficacy & safety of PDR001 in pts with nonfunctional well- & poorly-differentiated (diff) neuroendocrine neoplasms.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yao et al. (2018) studied this question.

synapsesocial.com/papers/6a7bfd1d050daa66a5df7872 https://doi.org/10.1093/annonc/mdy293.001

View Full Paper

Ask AI

Bookmark

Share

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Ask about this paper

Abstract

Discussion

Cite This Study

Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx)

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading